Shanghai Qilu Pharmaceutical Research and Development Center Ltd
Clinical trials sponsored by Shanghai Qilu Pharmaceutical Research and Development Center Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a new pill tame inflammatory bowel disease? early safety trial begins Results expected Jan 2027 (estimated)
-
Could a new pill tame inflammatory bowel disease? early safety trial begins
Disease control Not yet recruitingThis Phase 1 trial is testing an experimental oral drug called QLS1510, which is being developed for inflammatory bowel disease (IBD). The study enrolls healthy adults aged 18 to 45 to evaluate the drug's safety, tolerability, how it moves through the body, and the effect of food…
Phase 1 • Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug QLS1317 enters human trials
Disease control Not yet recruitingThis early-stage trial is testing a new drug called QLS1317 in 120 people with advanced solid tumors that have high microsatellite instability (MSI-H) or deficient DNA mismatch repair (dMMR). These patients have already tried standard treatments without success. The study aims to…
Phase 1 • Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC